Conducting a Virtual Clinical Trial in HER2-Negative Breast Cancer Using a Quantitative Systems Pharmacology Model With an Epigenetic Modulator and Immune Checkpoint Inhibitors
Hanwen Wang(Anhui Medical University), Aleksander S. Popel(Johns Hopkins University), Evanthia T. Roussos Torres(University of Southern California), Mohammad Jafarnejad(Johns Hopkins University), Elizabeth M. Jaffee(Bloomberg (United States)), Vered Stearns(Johns Hopkins University), Sondra Rahmeh(Johns Hopkins University), Richard J. Sové(Johns Hopkins University), Roisín M. Connolly(Johns Hopkins University)
Cited by 53
Related Papers
Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
|Science|2008|4k
CYP2D6 Genotype, Antidepressant Use, and Tamoxifen Metabolism During Adjuvant Breast Cancer Treatment
|JNCI Journal of the National Cancer Institute|2005|947
Active Tamoxifen Metabolite Plasma Concentrations After Coadministration of Tamoxifen and the Selective Serotonin Reuptake Inhibitor Paroxetine
|JNCI Journal of the National Cancer Institute|2003|850